ArticleWellcome open research2017
Antimalarial drugs and the prevalence of mental and neurological manifestations: A systematic review and meta-analysis.
Article in Wellcome open research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 22 citations in OpenAlex.
- Review
- Electrical Synapses Contribute to Sleep-Dependent Declarative Memory Retention.The European journal of neuroscience · 2026Article
- Comparative effects of antimalarial drugs on oxidative phosphorylation, mitochondrial dynamics and mitophagy inToxicology reports · 2025Article
- The role of breastfeeding, antibiotics and antimalarial medicinal exposure in paediatric depression amongst children aged under 5: a population-based study.BMC pediatrics · 2025Article
- Effects of anti-tau immunotherapy on reactive microgliosis, cerebral endotheliopathy, and cognitive function in an experimental model of cerebral malaria.Journal of neurochemistry · 2023Article
- Questionnaire-Based Analysis of Adverse Events and Compliance with Malaria Chemoprophylaxis in Taiwan.Journal of personalized medicine · 2023Article
- NADPH Oxidase: a Possible Therapeutic Target for Cognitive Impairment in Experimental Cerebral Malaria.Molecular neurobiology · 2022Article
- Strengthening therapeutic adherence and pharmacovigilance to antimalarial treatment in Manaus, Brazil: a multicomponent strategy using mHealth.Malaria journal · 2022Article
- The Ototoxicity of Antimalarial Drugs-A State of the Art Review.Frontiers in neurology · 2021Review
- Psychiatric adverse events with hydroxychloroquine during COVID-19 pandemic.Asian journal of psychiatry · 2020Article
- Neurological and psychiatric safety of tafenoquine in Plasmodium vivax relapse prevention: a review.Malaria journal · 2020Review
- Antiplasmodial and Cytotoxic Activities of Extracts of Selected Medicinal Plants Used to Treat Malaria in Embu County, Kenya.Journal of parasitology research · 2020Article
- Methanol extracts ofPharmaceutical biology · 2019Article
- Tafenoquine and primaquine do not exhibit clinical neurologic signs associated with central nervous system lesions in the same manner as earlier 8-aminoquinolines.Malaria journal · 2018Review
- Antimalarial drugs and the prevalence of mental and neurological manifestations: A systematic review and meta-analysis.Wellcome open research · 2017Article
- Atovaquone-proguanil exposure in pregnancy and risk for adverse fetal and infant outcomes: A retrospective analysis.Travel medicine and infectious diseaseArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.